ARCHIVES

NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study.

This article is from The Cancer Letter archive.

Vol. 31 No. 22 | June 3, 2005

Download PDF Visit The Full Archive

Related Articles

NCI Initiative: Start With Mechanism, Then answer The Many Questions, Klauser Says to Advisors

November 29, 1996

Olaparib, A PARP Inhibitor, Can Reduce Tumor Size In Advanced Ovarian Cancer

August 27, 2010

Funding Opportunities

February 7, 2003

Sen. Specter Seeks NCI Explanation of Delay in P-4 Breast Cancer Prevention Trial.

May 25, 2007

Anil Potti Resigns From Duke University

November 19, 2010

ORI Finds Misconduct By CIT Professor

August 4, 1995